MNOV$1.6156
Chart
Performance
Key Stats
AI MNOV Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyMediciNova shows potential with its pipeline, but faces significant hurdles with profitability and market perception. Thematic alignment is moderate, and technicals are mixed. Suitable for investors with a high-risk tolerance focusing on early-stage biopharma.
Thematic
MediciNova operates in the biopharmaceutical sector, focusing on novel therapeutics for serious diseases. While the underlying market for such treatments is strong, the company's specific therapeutic areas and stage of development influence its thematic appeal.
Fundamental
MediciNova has a strong cash position but is pre-revenue and currently unprofitable. Its balance sheet appears healthy for its stage, but valuation metrics are not applicable in the traditional sense due to lack of revenue and earnings.
Technical
The stock has experienced significant volatility but shows signs of recovery and positive short-term momentum. Key moving averages suggest a potential uptrend, but the stock is approaching resistance.
| Factor | Score |
|---|---|
| Neurodegenerative Diseases Treatment | 70 |
| Fibrotic and Metabolic Disorders Treatment | 55 |
| Biotechnology Innovation | 50 |
| Healthcare Sector Growth | 65 |
| Partnerships and Licensing | 60 |
| Factor | Score |
|---|---|
| Valuation | 40 |
| Profitability | 10 |
| Growth | 0 |
| Balance Sheet Health | 85 |
| Debt Management | 95 |
| Earnings Consistency (EPS Surprise) | 70 |
| Factor | Score |
|---|---|
| Trend Analysis | 75 |
| Momentum | 70 |
| Trading Volume | 80 |
| Support & Resistance | 60 |
| Short-Term Price Action | 70 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Positive Short-Term Performance
The stock has shown positive performance over multiple short-term periods: 5D (+17.74%), 1M (+9.77%). This indicates recent positive investor sentiment and momentum.
Broad Technical Buy Signals
Multiple technical indicators across various timeframes (1m, 5m, 15m, 30m, 1h, 2h, 4h) suggest 'Buy' or 'Neutral' signals for Exponential Moving Averages (EMAs) and Simple Moving Averages (SMAs), indicating underlying buying pressure.
Bearish Points (7)
Negative Earnings and Revenue
The company has consistently reported negative net income (e.g., -$11,049,549 in 2024Q4) and zero revenue in recent periods (2024Q4, 2022Q4), leading to often meaningless P/E ratios and indicating a lack of current profitability.
No Revenue Growth
Revenue figures are reported as $0 for 2024Q4, 2022Q4, and 2024 (annual), and low for other periods. This indicates a lack of commercialization or sales generation, a significant concern for a biopharmaceutical company.
Calendar
August 2025
15
Next Earnings Date
H: $-0.12
A: $-0.12
L: $-0.12
Profile
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2b/3 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. It is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia. The company has a license agreement with Kyorin Pharmaceuticals for the development and commercialization of MN-166 and MN-001. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
Seasonals
Price Target
7.00 USD
The 39 analysts offering 1 year price forecasts for MNOV have a max estimate of 9.00 and a min estimate of 5.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Cash Flow
Related Companies
Powered by LiveAIWeight: 98
Direct competitor in Amyotrophic Lateral Sclerosis (ALS) treatment development with an approved drug (Relyvrio), a key focus area for MNOV.
Weight: 97
Leading company developing a Non-alcoholic Steatohepatitis (NASH) treatment, representing a direct competitive or comparative landscape for MNOV's MN-001.
Weight: 95
Major player in Multiple Sclerosis (MS) therapeutics and also active in Amyotrophic Lateral Sclerosis (ALS) development, both primary therapeutic areas for MNOV's ibudilast (MN-166).
Weight: 94
Strong contender in NASH drug development, with a pipeline that offers a direct comparison to MNOV's efforts in this area.